Publications by authors named "Liesbeth Deberdt"
Article Synopsis
- The study assessed the effectiveness and safety of ziritaxestat, a medication targeting autotaxin, for treating early diffuse cutaneous systemic sclerosis (dcSSc) in a 24-week double-blind trial involving adults.
- Results showed that patients taking ziritaxestat had a significantly greater decrease in skin thickness (measured by MRSS) compared to those on a placebo, and the medication was generally well tolerated, with headaches and diarrhea being the most common side effects.
- Biomarker analysis indicated reductions in certain blood markers associated with fibrosis, suggesting ziritaxestat may help improve skin conditions in dcSSc patients through the modulation of the autotaxin/LPA pathway.
Background: Platelet (PLT) support is critical to the care of patients with thrombocytopenia, but allogeneic transfusions carry risk. Pathogen reduction mitigates some transfusion risks, but effects on PLT function remain a concern. This clinical pilot study assessed the effect of pathogen reduction technology with riboflavin plus ultraviolet light using thrombelastography (TEG).
View Article and Find Full Text PDF